Is silence still golden? Mapping the RNAi patent landscape

Nature Biotechnology

Volumn 29, Issue 6, 2011, Pages 493-497

  Lundin, Per ^a,b  

^a Life Science Practice at AlbihnsZacco   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

DOUBLE STRANDED RNA; SINGLE STRANDED RNA; SMALL INTERFERING RNA;

ARTICLE; CAENORHABDITIS ELEGANS; GENE MAPPING; INFECTION; NEOPLASM; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RESPIRATORY TRACT DISEASE; RNA INTERFERENCE;

DRUG APPROVAL; DRUG DELIVERY SYSTEMS; DRUG INDUSTRY; EUROPE; GENE TARGETING; PATENTS AS TOPIC; RNA INTERFERENCE; RNA, SMALL INTERFERING; UNITED STATES;

EID: 79958141092     PISSN: 10870156     EISSN: 15461696     Source Type: Journal    
DOI: 10.1038/nbt.1885     Document Type: Article

References (16)

1. Opko Health. Opko health announces update on phase III clinical trial of bevasiranib. http://investor.opko.com/releasedetail.cfm?ReleaseID=369294 (Opko Health, 6 March 2009).
2. Alnylam Pharmaceuticals. Alnylam and Cubist announce complete data from phase II study of ALNRSV01 in lung transplants patients naturally infected with respiratory syncytial virus http://phx.corporateir.net/preview/phoenix.zhtml?c= 148005&p=irolnewsArticle&ID=1308924&highlight= (Alnylam Pharmaceuticals, 20 July 2009).
3. Davis, M.E. et al. Nature 464, 1067-1070 (2010).
4. Couzin-Frankel, J. Science 330, 1163 (2010).
5. Macron, D. Pfizer to shut down oligo therapeutics unit as part of restructuring. Gene Silencing News http:// www.genomeweb.com/rnai/pfizer-shut- down-oligo-therapeutics- unit-part-restructuring (3 February 2011).
6. Ledford, H. Nature 468, 487 (2010).
7. Pollack, A. Drugmaker's fever for the power of RNA interference has cooled. The New York Times http://www.nytimes.com/2011/02/08/science/08rna.html? -r=1&scp=1&sq=rnai&st=cse (7 February 2011).
8. Fire, A. et al. Nature 391, 806-811 (1998).
9. Elbashir, S.M. et al. Nature 411, 494-498 (2001).
10. Lähteenmäki, R. & Lawrence, S. Nat. Biotechnol. 25, 729-737 (2007).
11. Yang, W. Nat. Biotechnol. 28, 116 (2010).
12. Huggett, B., Hodgson, J. & Lähteenmäki, R. Nat. Biotechnol. 27, 710-721 (2009).
13. European Patent Office. Decision of the administrative council of 25 March 2009 amending the implementing regulations to the European Patent Convention (CA/ D2/09). Official J. EPO 5, 296-298 (2010).
14. Jones, D. Nat. Rev. Drug Discov. 8, 525-526 (2009).
15. Burgess, P. et al. Nat. Biotechnol. 28, 1267-1270 (2010).
16. McLeod, B.W., Hayman, M.L., Purcell, A.L., Marcus, J.S. & Veithenheimer, E. Nat. Biotechnol. 29, 129-133 (2011).